Traws Pharma, Inc.
TRAWDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How TRAW's past catalysts played out
rigosertib sodium
Myelodysplastic Syndromes
ON 01910.Na
Myelodysplastic Syndrome
Gemcitabine
Metastatic Pancreatic Adenocarcinoma
rigosertib
Head and Neck Squamous Cell Carcinoma
Narazaciclib
Endometrioid Endometrial Cancer
Oral rigosertib
Myelodysplastic Syndromes
TRX-100
Influenza
Ratutrelvir (83-0060) non-randomised
COVID - 19
Azacitidine
Myelodysplastic Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rigosertib sodium | Phase 3 | Myelodysplastic Syndromes | - | - |
ON 01910.Na | Phase 3 | Myelodysplastic Syndrome | - | - |
Gemcitabine | Phase 3 | Metastatic Pancreatic Adenocarcinoma | - | |
rigosertib | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Narazaciclib | Phase 2 | Endometrioid Endometrial Cancer | - | - |
Oral rigosertib | Phase 2 | Myelodysplastic Syndromes | - | - |
TRX-100 | Phase 2 | Influenza | - | - |
Ratutrelvir (83-0060) non-randomised | Phase 2 | COVID - 19 | - | - |
Azacitidine | Phase 2 | Myelodysplastic Syndrome | - |
Myelodysplastic Syndromes
2 drugs in this indication
Myelodysplastic Syndrome
2 drugs in this indication
Metastatic Pancreatic Adenocarcinoma
1 drug in this indication
Endometrioid Endometrial Cancer
1 drug in this indication
COVID - 19
1 drug in this indication
Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Traws Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Traws Pharma, Inc.'s (TRAW) pipeline across Phase 3, Phase 2. Its lead program is rigosertib sodium (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Traws Pharma, Inc.'s next FDA catalyst?→
Traws Pharma, Inc.'s (TRAW) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TRAW biotech catalysts?→
Add TRAW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Traws Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.